Prioritisation and Risk Evaluation of Medicines in the EnviRonment (PREMIER)

Leading organisations:
Innovative Medicine Initiative


Geographic Area:


The Prioritisation and Risk Evaluation of Medicines in the EnviRonment, PREMIER project, aims to deliver a novel assessment system for characterising the environmental risks of APIs and which can be used to:
– Screen and prioritise legacy APIs for a tailored environmental assessment
– Identify potential hazards associated with APIs in development and explore the options to steer the design process in a greener direction
– Make relevant environmental data on APIs more visible and accessible to all stakeholders

Target audience:
Academics, Environmental experts, General Public, Health Professionals, Hospitals/health system stakeholders, Local governments, National/Local decision and policy makers, Patients, Pharmaceutical manufacturers, Pharmacists, Physicians, Scientists, Staff of wastewater treatment plants, Waste/water treatment providers, and Water/waste service providers

Area of interest:
Occurrence of pharmaceuticals in the environment, Pharmaceutical manufacturing, Risks to ecosystems, and Risks to human health


Communication material:

Return to search form.

HCWH Europe gratefully acknowledges the financial support of the European Commission (EC)’s LIFE+ programme, the Federal Ministry for the Environment, Nature Conservation, and Nuclear Safety (BMU) Germany, and the German Environment Agency (UBA). HCWH Europe is solely responsible for the content of this project and related materials. The views expressed do not reflect the official views of the EC, BMU, or UBA.